Startseite › Multiples Myelom › North Carolina › Durham
Klinische Studien zu Multiples Myelom in Durham, NC
37 Studien zu Multiples Myelom suchen Teilnehmer an Standorten in und um Durham (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Teilnehmer gesuchtPhase 3
- Research Site, Chapel Hill · 10 mi entfernt
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Teilnehmer gesuchtPhase 3
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Teilnehmer gesuchtPhase 2
- Duke University Medical Center, Durham
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Teilnehmer gesuchtPhase 3
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · 10 mi entfernt
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Teilnehmer gesuchtPhase 3
- Durham VAMC, Durham
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Teilnehmer gesuchtPhase 2/3
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · 10 mi entfernt
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Teilnehmer gesuchtPhase 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi entfernt
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Teilnehmer gesuchtPhase 3
- Duke University, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Teilnehmer gesuchtPhase 2
- University of North Carolina Medical Center, Chapel Hill · 10 mi entfernt
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Teilnehmer gesuchtPhase 1/2
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill · 10 mi entfernt
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Teilnehmer gesuchtPhase 2
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Teilnehmer gesuchtPhase 1
- University of North Carolina Hospitals at Hillsborough, Hillsborough · 13 mi entfernt
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Teilnehmer gesuchtPhase 1/2
- GSK Investigational Site, Chapel Hill · 10 mi entfernt
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Teilnehmer gesuchtPhase 1
- Duke University Hospital, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Teilnehmer gesuchtPhase 1/2
- Research Site, Durham
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Teilnehmer gesuchtPhase 3
- Research Site, Durham
- Research Site, Chapel Hill · 10 mi entfernt
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Teilnehmer gesucht
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · 10 mi entfernt
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Teilnehmer gesuchtPhase 1
- Duke Cancer Center, Durham
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Teilnehmer gesuchtPhase 2
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · 10 mi entfernt
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Teilnehmer gesuchtPhase 1/2
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · 10 mi entfernt
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Teilnehmer gesuchtPhase 1/2
- Duke Institute of Cancer/ Duke University, Durham
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Teilnehmer gesuchtPhase 1
- University of North Carolina /ID# 251203, Chapel Hill · 10 mi entfernt
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Teilnehmer gesuchtPhase 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi entfernt
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Teilnehmer gesuchtPhase 2
- University of North Carolina (Data Collection Only), Chapel Hill · 10 mi entfernt
Registry of Older Patients With Cancer
Teilnehmer gesuchtBeobachtungsstudie
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi entfernt
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Teilnehmer gesuchtPhase 3
- Duke University, Durham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Teilnehmer gesuchtPhase 2
- University of North Carolina, Chapel Hill · 10 mi entfernt
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
Teilnehmer gesuchtPhase 2
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi entfernt
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Teilnehmer gesuchtPhase 1
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · 10 mi entfernt
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Teilnehmer gesuchtPhase 1/2
- Duke University Health System (DUHS), Durham
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Teilnehmer gesuchtPhase 1
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · 13 mi entfernt
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Teilnehmer gesuchtPhase 1
- University of North Carolina, Chapel Hill · 10 mi entfernt
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Teilnehmer gesuchtPhase 1
- University of North Carolina, Chapel Hill · 10 mi entfernt
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Teilnehmer gesuchtPhase 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · 10 mi entfernt
Registry for Adults With Plasma Cell Disorders (PCD's)
Teilnehmer gesuchtBeobachtungsstudie
- North Carolina Cancer Hospital, Chapel Hill · 10 mi entfernt
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Teilnehmer gesuchtBeobachtungsstudie
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi entfernt
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Teilnehmer gesuchtPhase 1
- Duke University Health System (DUHS), Durham
Multiples Myelom-Studien in anderen Städten
- New York City, NY60 Studien
- Boston, MA42 Studien
- Atlanta, GA41 Studien
- Houston, TX38 Studien
- Nashville, TN32 Studien
- Denver, CO27 Studien
- Rochester, MN24 Studien
- St. Louis, MO24 Studien
- Columbus, OH24 Studien
- Baldwin Park, CA23 Studien
- Chicago, IL22 Studien
- Seattle, WA22 Studien
Weitere Studien in Durham
- Brustkrebs63 Studien
- Krebs (alle Arten)58 Studien
- Nichtkleinzelliges Lungenkarzinom39 Studien
- Metastasierender Krebs33 Studien
- Akute myeloische Leukämie33 Studien
- Lungenkrebs32 Studien
- Prostatakrebs32 Studien
- Kolorektales Karzinom28 Studien
- Chronische lymphatische Leukämie27 Studien
- Eierstockkrebs27 Studien
- Herzinsuffizienz26 Studien
- Bauchspeicheldrüsenkrebs24 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 05.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.